AQUACYS
LIVE

Serial Number

99663191

Owner

Aarvik Therapeutics, Inc.

Attorney

Christopher D Olszyk, Jr.

Filing Date

Feb 20, 2026

Add to watchlist:

No watchlists yet
View on USPTO

AQUACYS Trademark

Serial Number: 99663191

AQUACYS is a trademark filed by Aarvik Therapeutics, Inc. on February 20, 2026. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Aarvik Therapeutics, Inc. (7 trademarks)

Hayward, CA 94544

Entity Type: 03

Trademark Details

Filing Date

February 20, 2026

Registration Date

Not Registered

Goods & Services

Antibody technology platform incorporating engineered cysteines for use in conjugating cysteine reactive small and large molecules, for medical diagnosis and treatment purposes; Antibody technology platform incorporating engineered cysteines for use in conjugating cysteine reactive small and large molecules, resulting in conjugates with improved hydrophilicity, for medical diagnosis and treatment purposes; Antibody technology platform used to incorporate cysteines into an antibody, namely protein arrays, for medical diagnosis and treatment purposes; Delivery devices for antibodies, namely, drug delivery agents in the form of antibody conjugates that facilitate the delivery and action of medical preparations; Antibody products, namely, antibody conjugates for medical diagnosis and treatment in the fields of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders; Chemical, biological and biochemical products for medical and pharmaceutical use, namely, antibody conjugates; Pharmaceutical preparations, namely antibody conjugates, for use in the diagnosis and treatment of diseases, namely, cancer, inflammatory disease, infectious disease and neurologic diseases and disorders; Large and small molecules, namely, reagents, antibody fragments, antibodies, all intended for use in medical diagnosis and disease treatment; Pharmaceutical products, preparations and medical articles, namely, antibodies, antibody conjugates and active principles for medical diagnosis and disease treatment

Research and development of antibody conjugates; Scientific research for medical purposes in the field of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders; Research and development services in the field of antibodies; Scientific and technological services and research relating thereto, namely, scientific research, analysis and testing in the fields of antibody conjugates; Antibody engineering; Custom design and engineering of antibodies; Research and development of pharmaceuticals for the treatment of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Research, development and establishment of testing specifications and procedures in the fields of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders research, diagnosis and treatment; Providing scientific research information in the fields of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders research, diagnosis and treatment

Antibodies and antibody conjugates for scientific purposes, other than for medical or veterinary purposes; Antibody conjugates for use in the formation of nanoparticles, for scientific and medical research; Chemical substances for the formation of antibody conjugates for use in scientific and medical research; Diagnostic products for scientific and medical research use in the field of antibody conjugates for scientific and medical research; Antibody conjugate technology platform used to incorporate cysteines into an antibody, namely, protein arrays and nucleotide arrays for scientific and medical research; Antibody technology platform incorporating engineered cysteines for use in conjugating cysteine reactive small and large molecules, resulting in conjugates with improved hydrophilicity, for scientific and medical research; Antibody technology platform incorporating engineered cysteines for use in conjugating cysteine reactive small and large molecules, for scientific and medical research; Chemical, biochemical and biological reagents for scientific or medical research use

Filing History

NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 12, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jun 12, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jun 12, 2026 CNRT
ASSIGNED TO EXAMINER
Jun 10, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 22, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Feb 20, 2026 MAFR
NEW APPLICATION ENTERED
Feb 20, 2026 NWAP